Video

Dr. Phillips on Navigating Treatment Selection With BTK Inhibitors in MCL

Tycel Jovelle Phillips, MD, discusses navigating treatment selection with BTK inhibitors in mantle cell lymphoma.

Tycel Jovelle Phillips, MD, clinical associate professor, Division of Hematology and Oncology, Department of Internal Medicine, Rogel Cancer Center, Michigan Medicine, discusses navigating treatment selection with BTK inhibitors in mantle cell lymphoma (MCL).

The published data in the space suggest that there could be an efficacy difference when deciding between the BTK inhibitors acalabrutinib (Calquence), zanubrutinib (Brukinsa), and ibrutinib (Imbruvica), Phillips says. However, the patient populations evaluated in the clinical trials of acalabrutinib and zanubrutinib were less pretreated compared with that treated with ibrutinib. Moreover, the clinical trials utilized different criteria. In turn, this may have resulted in an underestimation of response with ibrutinib, Phillips adds.

Overall, it is widely accepted that the 3 inhibitors are equally efficacious, Phillips continues. However, data suggest there could be safety differences between the later-generation agents acalabrutinib and zanubrutinib vs ibrutinib, the former of which appear to have a more favorabletoxicity profile. As these agents have not been compared head-to-head, comparing the toxicity profiles requires cross-trial comparison, which is not preferred. However, without the direct comparisons, informed decisions are being made off available data, Phillips concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity